Last reviewed · How we verify
NCT05111743
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
trial testing Brolucizumab in Age-related Macular Degeneration (AMD) in 9,261 participants. Completed in 18 December 2020.
18 December 2020
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9,261 |
| Start date | 17 June 2020 |
| Primary completion | 18 December 2020 |
| Estimated completion | 18 December 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Brolucizumab (BROLUCIZUMAB) — full drug profile →
Conditions studied
- Age-related Macular Degeneration (AMD) — all drugs for Age-related Macular Degeneration (AMD) →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 18 to 85, any sex, with Age-related Macular Degeneration (AMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet AMD patients initiating brolucizumab. Evidence was generated to describe their patient characteristics and clinical outcomes. The study was conducted using the Komodo Healthcare Map.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05111743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brolucizumab
Trials testing the same drug.
- NCT05710471 — Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E · Phase 4 · completed
- NCT05266495 — Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting · terminated
- NCT04774926 — Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With · Phase 4 · completed
- NCT05657158 — Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retin · completed
- NCT04679935 — Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration · Phase 4 · completed
Other recruiting trials for Age-related Macular Degeneration (AMD)
Currently open trials in the same condition.
- NCT06541704 — A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult · Phase 3 · recruiting
- NCT07084883 — Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneratio · recruiting
- NCT04292080 — Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy · Phase 2 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05111743 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 21 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05111743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing